Trial · NCT03350035
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Did Not Require an IV Anesthetic Drug for SE Treatment | Low - GNX | 5 | Participants | ||
| Number of Participants Who Did Not Require an IV Anesthetic Drug for SE Treatment | Medium - GNX | 4 | Participants | ||
| Number of Participants Who Did Not Require an IV Anesthetic Drug for SE Treatment | High - GNX | 8 | Participants | ||
| Time to Cessation of SE | Low - GNX | 5.000 | Full Range 2.45 to 6.05 | Minutes | |
| Time to Cessation of SE | Medium - GNX | 5.580 | Full Range 4.18 to 22.25 | Minutes | |
| Time to Cessation of SE | High - GNX | 10.16 | Full Range 1.34 to 241.00 | Minutes | |
| Number of Participants Who Required No Escalation of Treatment for Ongoing or Recurrent SE | Low - GNX | 3 | Participants | ||
| Number of Participants Who Required No Escalation of Treatment for Ongoing or Recurrent SE | Medium - GNX | 3 | Participants | ||
| Number of Participants Who Required No Escalation of Treatment for Ongoing or Recurrent SE | High - GNX | 8 | Participants | ||
| Number of Participants With No SE Recurrence Per Principal Investigator | Low - GNX | Within 24hrs of starting treatment | 5 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | Medium - GNX | Within 24hrs of starting treatment | 4 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | High - GNX | Within 24hrs of starting treatment | 7 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | Low - GNX | During treatment period (excluding taper) | 3 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | Medium - GNX | During treatment period (excluding taper) | 4 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | High - GNX | During treatment period (excluding taper) | 7 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | Low - GNX | During taper | 3 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | Medium - GNX | During taper | 2 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | High - GNX | During taper | 7 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | Low - GNX | During 24-hr follow-up period | 3 | Participants | |
| Number of Participants With No SE Recurrence Per Principal Investigator | Medium - GNX | During 24-hr follow-up period | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03350035/results